The short version of peptide mapping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-26 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
==== United Kingdom ==== On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)". The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexylamines, including 3-MeO-PCP.
BMR (Males) in Kcals/day = 9.99 (weight in kg) + 6.25 (height in cm) – 4.92 (age in years) + 5 BMR (Females) in Kcals/day = 9.99 (weight in kg) + 6.25 (height in cm) – 4.92 (age in years) – 161 The Mifflin St. Jeor Equation has been found to be the most accurate predictor of BMR compared to BMR measured by direct and indirect calorimetry.
Centrifugation is a process that uses centrifugal force to separate mixtures of particles of varying masses or densities suspended in a liquid. When a vessel (typically a tube or bottle) containing a mixture of proteins or other particulate matter, such as bacterial cells, is rotated at high speeds, the inertia of each particle yields a force in the direction of the particles velocity that is proportional to its mass. The tendency of a given particle to move through the liquid because of this force is offset by the resistance the liquid exerts on the particle. The net effect of "spinning" the sample in a centrifuge is that massive, small, and dense particles move outward faster than less massive particles or particles with more "drag" in the liquid. When suspensions of particles are "spun" in a centrifuge, a "pellet" may form at the bottom of the vessel that is enriched for the most massive particles with low drag in the liquid. Non-compacted particles remain mostly in the liquid called "supernatant" and can be removed from the vessel thereby separating the supernatant from the pellet. The rate of centrifugation is determined by the angular acceleration applied to the sample, typically measured in comparison to the g-force. If samples are centrifuged long enough, the particles in the vessel will reach equilibrium wherein the particles accumulate specifically at a point in the vessel where their buoyant density is balanced with centrifugal force. Such an "equilibrium" centrifugation can allow extensive purification of a given particle.
==== Mining and extraction of fuels ==== According to the World Nuclear Association, coal from all deposits contains traces of various radioactive substances, particularly radon, uranium and thorium. These substances are released during coal mining, especially from surface mines, through power plant emissions, or power plant ash, and contribute to terrestrial radiation exposure through their exposure pathways. In December 2009, it was revealed that oil and gas production generates millions of tons of radioactive waste each year, much of which is improperly disposed of without detection, including 226Radium and 210Polonium. The specific activity of the waste ranges from 0.1 to 15,000 becquerels per gram. In Germany, according to the Radiation Protection Ordinance of 2001, the material is subject to monitoring at one Becquerel per gram and would have to be disposed of separately. The implementation of this regulation has been left to the industry, which has disposed of the waste carelessly and improperly for decades.
== Techniques for data analysis == Global proteome profiling is the direct representation of the protein set in an organism, organ, tissues, or an organelle. Among the primary goals of proteomic analysis is to compare and determine the relative quantities of proteins under a defined set of conditions. Over the last 4 decades, two-dimensional gel electrophoresis has gained popularity because it successfully helped differential proteomics provide visual proof of changes in protein abundance that cannot be predicted from genome analysis. Each protein spot on a 2-DE gel can be analyzed based on its abundance, location, or even presence and absence. This flexible gel-based method combines and makes use of the best principle for separation of protein complexes based on their charge and mass, visual mapping coupled with successful mass spectrometric identification of individual proteins. Latest developments in proteomics have paved the way for the discovery of techniques such as colocalization analysis (COLA), which detects protein–protein co-localizations at a global scale. This helps map interactome dynamics under various conditions, making it possible to understand protein interactions and functions. Proteomic profiling relates to each individual's physiological changes by the monitoring of protein expression variations according to factors such as aging, exercise, and environmental conditions. For example, in aging muscle, proteomic analysis showed changes in protein isoforms and altered metabolic pathways that indicate adaptations in muscle functions and energy metabolism.
Sources: en.wikipedia.org
Martin Fleischmann of the University of Southampton and Stanley Pons of the University of Utah hypothesized that the high compression ratio and mobility of deuterium that could be achieved within palladium metal using electrolysis might result in nuclear fusion. To investigate, they conducted electrolysis experiments using a palladium cathode and heavy water within a calorimeter, an insulated vessel designed to measure process heat. Current was applied continuously for many weeks, with the heavy water being renewed at intervals. Some deuterium was thought to be accumulating within the cathode, but most was allowed to bubble out of the cell, joining oxygen produced at the anode. For most of the time, the power input to the cell was equal to the calculated power leaving the cell within measurement accuracy, and the cell temperature was stable at around 30 °C. But then, at some point (in some of the experiments), the temperature rose suddenly to about 50 °C without changes in the input power. These high temperature phases would last for two days or more and would repeat several times in any given experiment once they had occurred. The calculated power leaving the cell was significantly higher than the input power during these high temperature phases. Eventually the high temperature phases would no longer occur within a particular cell. In 1988, Fleischmann and Pons applied to the United States Department of Energy for funding towards a larger series of experiments. Up to this point they had been funding their experiments using a small device built with $100,000 out-of-pocket.
Darbar ( transl. Court) is a 2020 Indian Tamil-language action thriller film written and directed by AR Murugadoss, and produced by Allirajah Subaskaran under the banner Lyca Productions. The film stars Rajinikanth, Suniel Shetty, Nayanthara and Nivetha Thomas. It follows Aaditya Arunasalam (Rajinikanth), the commissioner of Mumbai Police, who sets out to curb the city's rampant drug-trafficking and prostitution. When he uncovers a deep controversy linked to an international drug lord, however, he tries to fulfill his secret agenda. The film is Rajinikanth's first role as a police officer in 27 years following Pandiyan (1992). The project's working title was Thalaivar 167 and the title Darbar was officially announced on 9 April 2019. Principal photography commenced the same month, mostly in Mumbai, and was completed in October 2019. Anirudh Ravichander composed the music for the film. The cinematographer was Santosh Sivan and the editor was A. Sreekar Prasad. Darbar was released theatrically in India on 9 January 2020, coinciding with the Pongal festival. The film met with mixed reviews upon release with praise for Rajinikanth’s performance and grossed ₹250 crore at the box office, making it the highest-grossing Tamil film of 2020 and 4th highest-grossing Indian film of 2020. Darbar became Rajinikanth’s fifth film to gross over ₹200 crore worldwide, following Enthiran, Kabali, 2.0, and Petta.
=== Flower and fruit === The flowers are monoecious, and open with or before the leaves. Once fully grown, these leaves are usually 3–6 millimetres (1⁄8–1⁄4 in) long on three-flowered clusters in the axils of the scales of drooping or erect catkins or aments. Staminate catkins are pendulous, clustered, or solitary in the axils of the last leaves of the branch of the year or near the ends of the short lateral branchlets of the year. They form in early autumn and remain rigid during the winter. The scales of the mature staminate catkins are broadly ovate, rounded, yellow or orange colour below the middle and dark chestnut brown at apex. Each scale bears two bractlets and three sterile flowers, each flower consisting of a sessile, membranous, usually two-lobed, calyx. Each calyx bears four short filaments with one-celled anthers or strictly, two filaments divided into two branches, each bearing a half-anther. Anther cells open longitudinally. The pistillate segments are erect or pendulous, and solitary, terminal on the two-leaved lateral spur-like branchlets of the year. The pistillate scales are oblong-ovate, three-lobed, pale yellow-green often tinged with red, becoming brown at maturity. These scales bear two or three fertile flowers, each flower consisting of a naked ovary. The ovary is compressed, two-celled, and crowned with two slender styles; the ovule is solitary. Each scale bears a single small, winged nut that is oval, with two persistent stigmas at the apex.
Thylakoids (sometimes spelled thylakoïds), are small interconnected sacks which contain the membranes that the light reactions of photosynthesis take place on. The word thylakoid comes from the Greek word thylakos which means "sack". Suspended within the chloroplast stroma is the thylakoid system, a highly dynamic collection of membranous sacks called thylakoids where chlorophyll is found and the light reactions of photosynthesis happen. In most vascular plant chloroplasts, the thylakoids are arranged in stacks called grana, though in certain C4 plant chloroplasts and some algal chloroplasts, the thylakoids are free floating.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.